Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BMS 200604 01; Orzel; UFT; Uftoral

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Merck KGaA; Otsuka Pharmaceutical; Taiho Pharmaceutical
  • Class Antineoplastics; Nitrogen mustard compounds; Pyrimidinones
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Pancreatic cancer
  • Phase III Cervical cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 05 Nov 2022 Adverse events and efficacy data from a phase III GOTIC-002 LUFT trial in Cervical cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 01 May 2021 Taiho Pharmaceutical completes a phase III trial for Colorectal cancer (Adjuvant therapy) in Japan, prior to May 2021 (PO) (UMIN000005594)
  • 01 Jul 2011 Taiho Pharmaceutical initiates enrolment in a phase III trial for Colorectal cancer (Adjuvant therapy) in Japan (PO) (UMIN000005594)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top